FindTrial
Sign In

To check safety, effectiveness and utility of vortioxetine as initial line therapy in the Management of depression

To assess the safety, effectiveness and utility of vortioxetine as initial line therapy in the Management of depression through an observational, multicenter Study - IMPRESS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/09/073258
Enrollment
3500
Registered
2024-09-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F329- Major depressive disorder, singleepisode, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Torrent Pharmaceuticals Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult Male or female patients Treatment Naïve or known cases of MDD and treated with Vortioxetine as initial line therapy

Exclusion criteria

Exclusion criteria: Are allergic to vortioxetine or any of the ingredients in medicine

Design outcomes

Primary

MeasureTime frame
Safety assessment Usage pattern for Vortioxetine o Dose of Vortioxetine o Duration of Vortioxetine therapy o Co-prescription(s) along with Vortioxetine Timepoint: At 4 week—

Secondary

MeasureTime frame
Change in depression severity based on PHQ-9 scores Demographic pattern Physician Global Assessment on Effectiveness of Vortioxetine Patient treatment acceptability Prevalence of other co-morbid conditions along with Depression Prescribed medications used for co-morbid conditions along with depression Timepoint: At 4 week—

Countries

India

Contacts

Public ContactDr Krishnaprasad K

OM psychiatric clinic

vishaldamani123@proton.me7096586855

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026